Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03167619
Recruitment Status : Recruiting
First Posted : May 30, 2017
Last Update Posted : August 19, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Sarah Sammons, MD, Duke University

Brief Summary:
This is a randomized, international, multicenter, Phase II study designed to explore the efficacy of olaparib or olaparib in combination with durvalumab in platinum-treated mTNBC. The primary objectives are to explore olaparib or olaparib in combination with durvalumab as maintenance therapy following clinical benefit with platinum-based therapy in subjects with mTNBC.

Condition or disease Intervention/treatment Phase
Triple Negative Breast Cancer Drug: Olaparib Oral Product Drug: Olaparib Oral Product in combination with Durvalumab Phase 2

Detailed Description:

Subjects suitable for enrollment into this trial are adult subjects with histologically documented triple negative adenocarcinoma of the breast that is inoperable, locally advanced, or metastatic, and is not amenable to resection with curative intent, and who have received at least 4 cycles of platinum-based chemotherapy in the 1st or 2nd line setting AND derived clinical benefit (CR / PR / SD) per RECIST 1.1 with platinum-based therapy as determined by the treating physician.

Eligible subjects will be randomized to either olaparib or olaparib in combination with durvalumab. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination. Upon treatment discontinuation, subjects will be followed every 2 months for survival.

Although randomization will be used to allocate subjects to either the olaparib or olaparib in combination with durvalumab arm, no comparisons between treatment regimens are planned. The purpose of randomization was to reduce bias due to subject selection into either treatment arm.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer
Actual Study Start Date : October 4, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: A - olaparib alone
Twice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
Drug: Olaparib Oral Product
olaparib 300mg twice daily

Experimental: B - olaparib plus durvalumab
Twice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
Drug: Olaparib Oral Product in combination with Durvalumab
olaparib 300mg twice daily plus intravenous durvalumab every 28 days




Primary Outcome Measures :
  1. Efficacy as assessed by PFS [ Time Frame: From date of randomization until the date of documented progression or date of death, whichever came first, approximately 1 year. ]
    To determine the efficacy as assessed by PFS of maintenance olaparib or olaparib in combination with durvalumab following clinical benefit (complete response [CR], partial response [PR] or stable disease [SD]) with platinum based chemotherapy in the 1st or 2nd line setting for treatment of metastatic triple negative breast cancer (mTNBC).


Secondary Outcome Measures :
  1. Overall Survival Olaparib alone [ Time Frame: study duration, approximately 2 years ]
    To determine the efficacy of maintenance olaparib following platinum based chemotherapy as assessed by overall survival (OS).

  2. Overall Survival olaparib in combination with Durvalumab [ Time Frame: study duration, approximately 2 years ]
    To determine the efficacy of maintenance olaparib in combination with durvalumab following platinum based chemotherapy as assessed by overall survival (OS).

  3. Determine safety and tolerability as determined by adverse events of maintenance olaparib alone. [ Time Frame: through study completion, approximately 1 year ]
    Determine safety and tolerability of maintenance olaparib following platinum based chemotherapy.

  4. Determine safety and tolerability as determined by adverse events of maintenance olaparib plus durvalumab [ Time Frame: through study completion, approximately 1 year ]
    Determine safety and tolerability of maintenance olaparib in combination with durvalumab following platinum based chemotherapy.

  5. Olaparib alone overall response rate (ORR) [ Time Frame: through study completion, approximately 1 year ]
    To determine the efficacy of maintenance olaparib following platinum-based chemotherapy as assessed by overall response rate (ORR).

  6. Olaparib in combination with Durvalumab overall response rate (ORR) [ Time Frame: through study completion, approximately 1 year ]
    To determine the efficacy of maintenance olaparib in combination with durvalumab following platinum-based chemotherapy as assessed by overall response rate (ORR).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 21 years of age
  2. ECOG performance status 0-2
  3. Inoperable locally advanced or metastatic breast cancer not amenable to resection with curative intent and histologically confirmed to be estrogen receptor (ER) negative, progesterone receptor (PR) negative, and HER2 negative:

    • ER status is defined as ≤ 10% tumor cells positive for ER by immunohistochemistry (IHC), irrespective of staining intensity
    • PR status is defined as ≤ 10% tumor cells positive for PR by IHC, irrespective of staining intensity
    • HER2 negative status is determined by:
    • IHC 1+, as defined by incomplete membrane staining that is faint/barely perceptible and within > 10% of invasive tumor cells, or
    • IHC 0, as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within ≤ 10% of the invasive tumor cells, or
    • FISH negative based on:
    • Single-probe average HER2 copy number < 4.0 signals / cell, or
    • Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals / cell
  4. Minimum six 1-weekly doses or three 3-weekly doses of platinum chemotherapy (monotherapy or combination therapy at investigator's discretion) with stable disease (SD), partial response (PR) or complete response (CR) to the platinum therapy as assessed by investigator.
  5. Has received no more than 2 prior chemotherapy regimens for metastatic breast cancer including current platinum based chemotherapy.
  6. Able to provide a representative formalin-fixed, paraffin embedded tumour specimen archival or fresh tissue for correlative studies and biomarker analysis.
  7. Hemoglobin ≥ 9.0 g/dL and no blood transfusions in the 28 days prior to study entry. Absolute neutrophil count ≥1,500/mm3. Platelet count ≥100 x 10^9/L.
  8. Total bilirubin <1.5 x the upper limit of normal (ULN) with the following exception: subjects with known Gilbert's disease who have serum bilirubin <3 x ULN may be enrolled.
  9. Aspartate transaminase (AST) and alanine transaminase (ALT) <2.5 x ULN with the following exceptions: subjects with documented liver or bone metastases may have AST and ALT <5 x ULN.
  10. Alkaline phosphatase (ALP) <2 x ULN (<5 x ULN in subjects with known liver involvement and <7 ULN in subjects with known bone involvement).
  11. Serum creatinine <1.5 x ULN or creatinine clearance >51 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
  12. For subjects of childbearing potential, agreement (by both subject and partner) to use two effective forms of contraception, including surgical sterilization, reliable barrier method, birth control pills, contraceptive hormone implants, or true abstinence and to continue its use for the duration of the study and for 3 months after last dose of study treatment.
  13. Subjects of childbearing potential should have a negative urine or serum pregnancy test during their screening visit. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  14. Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.
  15. For inclusion in genetic research, subjects must provide informed consent for genetic research collection of specimens to be stored at repository for future research.

Exclusion Criteria:

  1. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of first dose of treatment. Subjects who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks since last dose of the previous investigational agent or device.
  2. Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study or the follow-up period of an interventional study.
  3. Active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, or similar treatment) is not considered a form of systemic treatment.
  4. Is taking chronic systemic steroids in doses > 10mg of prednisolone or equivalent within 7 days prior to the first dose of trial treatment.
  5. Previous treatment with PARP inhibitors including olaparib.
  6. Received prior therapy with an anti-PD-1, anti-PD-L1 (including durvalumab) or an anti-PD-L2 agent.
  7. Known active central nervous system metastasis and / or carcinomatous meningitis. Subjects with previously treated brain metastases may participate, provided they have:

    1. Stable brain metastases [without evidence of progression by imaging (confirmed by computerized tomography {CT} scan if CT used at prior imaging) for at least four weeks prior to the first dose of trial treatment**,
    2. No evidence of new or enlarging brain metastases; any neurologic symptoms should have returned to baseline,
    3. Not used steroids for brain metastases in the 7 days prior to trial initiation. Taking chronic systemic steroids in doses ≤ 10mg of prednisolone is allowed.

      • This exception does not include carcinomatous meningitis, as subjects with carcinomatous meningitis are excluded regardless of clinical stability.
  8. History and/or confirmed pneumonitis, or extensive bilateral lung disease on high resolution/spiral CT scan.
  9. Patients with suspected or confirmed myelodysplastic syndrome/acute myeloid leukemia.
  10. History of another primary malignancy except for:

    1. Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study drug and of low potential risk for recurrence.
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    3. Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in situ.
  11. Major surgery within 2 weeks of starting the study, and subjects must have recovered from any effects of any major surgery.
  12. Receipt of radiation therapy within 4 weeks prior to starting study drug(s). Limited field of radiation for palliation within 2 weeks of the first dose of study treatment is allowed provided:

    1. The lung is not in the radiation field
    2. Irradiated lesion(s) cannot be used as target lesions
  13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease, active bleeding diatheses including any subjects known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness / social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent.
  14. Subjects unable to swallow orally administered medication, and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication.
  15. Subjects requiring treatment with potent inhibitors or inducers of CYP3A4.
  16. Pregnant or breast-feeding women. If breastfeeding can be stopped prior to study enrollment until 1 month after the last study dose, then the patient could be allowed to enter the study.
  17. Immunodeficient subjects, eg, subjects who are known to be serologically positive for human immunodeficiency virus (HIV).
  18. Received a live vaccine within 30 days of planned start of study therapy.
  19. Subjects with a known hypersensitivity to olaparib or durvalumab, or any of the excipients of the product.
  20. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)
  21. History of allogeneic organ transplant
  22. Active bleeding diatheses
  23. Patients with known active hepatic disease (ie, Hepatitis B or C)
  24. Known history of previous clinical diagnosis of tuberculosis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03167619


Contacts
Layout table for location contacts
Contact: Project Leader 1-919-668-7356 DORA@duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke University Recruiting
Durham, North Carolina, United States, 27705
Contact: Sarah Sammons, MD         
Sponsors and Collaborators
Duke University
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Sarah Sammons, MD Duke Cancer Institute

Layout table for additonal information
Responsible Party: Sarah Sammons, MD, Assistant Professor of Medicine, Duke University
ClinicalTrials.gov Identifier: NCT03167619     History of Changes
Other Study ID Numbers: Pro00080769
First Posted: May 30, 2017    Key Record Dates
Last Update Posted: August 19, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sarah Sammons, MD, Duke University:
Mestastic
Platinum Sensitive
Advanced
PARP inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Durvalumab
Olaparib
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action